Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

References

• Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–4544. doi:10.1200/JCO.2005.04.4859
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 2021;22(1):51–65. doi:10.1016/S1470-2045(20)30539-8
   PubMed Web of Science ®Google Scholar
• Rikitake Y, Mandai K, Takai Y. The role of nectins in different types of cell-cell adhesion. J Cell Sci. 2012;125(Pt 16):3713–3722. doi:10.1242/jcs.099572
   PubMed Web of Science ®Google Scholar
• Sloan KE, Eustace BK, Stewart JK, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 2004;4(1):73. doi:10.1186/1471-2407-4-73
   PubMedGoogle Scholar
• Kamran N, Takai Y, Miyoshi J, et al. Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PLoS One. 2013;8(1):e54406. doi:10.1371/journal.pone.0054406
   PubMed Web of Science ®Google Scholar
• Xu Y, Cui G, Jiang Z, et al. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett. 2019;17(3):2960–2968. doi:10.3892/ol.2019.9910
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57. doi:10.1038/ni.1674
   PubMed Web of Science ®Google Scholar
• Boles KS, Vermi W, Facchetti F, et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol. 2009;39(3):695–703. doi:10.1002/eji.200839116
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA. 2009;106(42):17858–17863. doi:10.1073/pnas.0903474106
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang H, Li M, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013;20(3):456–464. doi:10.1038/cdd.2012.141
   PubMed Web of Science ®Google Scholar
• Li M, Xia P, Du Y, et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling. J Biol Chem. 2014;289(25):17647–17657. doi:10.1074/jbc.M114.572420
   PubMed Web of Science ®Google Scholar
• Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2 -mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532–2537. doi:10.1200/JCO.2018.77.9777
   PubMed Web of Science ®Google Scholar
• Kučan Brlić P, Lenac Roviš T, Cinamon G, et al. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 2019;16(1):40–52. doi:10.1038/s41423-018-0168-y
   PubMed Web of Science ®Google Scholar
• Nishiwada S, Sho M, Yasuda S, et al. Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res. 2015;35(4):2287–2297.
   PubMed Web of Science ®Google Scholar
• Triki H, Charfi S, Bouzidi L, et al. CD155 expression in human breast cancer: clinical significance and relevance to natural killer cell infiltration. Life Sci. 2019;231:116543. doi:10.1016/j.lfs.2019.116543
   PubMed Web of Science ®Google Scholar
• American Association for Cancer Research. Tiragolumab Impresses in Multiple Trials, in Cancer Discov. United States: ©2020 American Association for Cancer Research; 2020:1086–1087.
   Google Scholar
• Bendell JC, Bedard P, Bang Y-J, et al. Abstract CT302: phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors. Cancer Res. 2020;80(16_Supplement):CT302. doi:10.1158/1538-7445.AM2020-CT302
   Web of Science ®Google Scholar
• Kurtulus S, Sakuishi K, Ngiow S-F, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125(11):4053–4062. doi:10.1172/JCI81187
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732. doi:10.1038/s41590-018-0132-0
   PubMed Web of Science ®Google Scholar
• Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186(3):1338–1342. doi:10.4049/jimmunol.1003081
   PubMed Web of Science ®Google Scholar
• Lozano E, Dominguez-Villar M, Kuchroo V, et al. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012;188(8):3869–3875. doi:10.4049/jimmunol.1103627
   PubMed Web of Science ®Google Scholar
• Grapin M, Richard C, Limagne E, et al. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J ImmunoTher Cancer. 2019;7(1):160. doi:10.1186/s40425-019-0634-9
   PubMedGoogle Scholar
• Whelan S, Ophir E, Kotturi MF, et al. PVRIG and PVRL2 are induced in cancer and inhibit CD8+ T-cell function. Cancer Immunol Res. 2019;7(2):257–268. doi:10.1158/2326-6066.CIR-18-0442
   PubMed Web of Science ®Google Scholar
• Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, Phase 2 study. Lancet Oncol. 2022;23(6):781–792. doi:10.1016/S1470-2045(22)00226-1
   PubMed Web of Science ®Google Scholar
• Genentech reports interim results for phase III SKYSCRAPER-01 study in PD-L1 high metastatic non-small cell lung cancer; 2022. Available from: https://www.gene.com/media/press-releases/14951/2022-05-10/genentech-reports-interim-results-for-ph. Accessed December 22, 2022.
   Google Scholar
• Rudin CM, Liu SV, Lu S. SKYSCRAPER-02: primary results of a Phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol. 2022;40(17_suppl):LBA8507.
   Web of Science ®Google Scholar
• Genentech provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer; 2022. Available from: https://www.gene.com/media/press-releases/14947/2022-03-29/genentech-provides-update-on-phase-iii-s. Accessed December 22, 2022.
   Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369–2379. doi:10.1200/JCO.20.00793
   PubMed Web of Science ®Google Scholar
• Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346–360.e7. doi:10.1016/j.ccell.2020.12.014
   PubMed Web of Science ®Google Scholar